Verrica Pharmaceuticals Inc. — fact timeline

Verrica Pharmaceuticals Inc. shareholders approved Approval of the Company’s Amended and Restated 2018 Equity Incentive Plan in the form attached as Appendix A to the Proxy Statement. at the 2026-06-05 meeting.

“Proposal No. 4 : Approval of the Company’s Amended and Restated 2018 Equity Incentive Plan in the form attached as Appendix A to the Proxy Statement. The votes were cast as follows: Votes For Votes Against Abstained Approval of the Company’s Amended and Restated 2018 Equity Incentive Plan 11,142,881 433,852 36,469 Broker Non-Votes: 2,456,129”

Verrica Pharmaceuticals Inc. shareholders approved Ratification of the selection of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-05 meeting.

“Proposal No. 3 : Ratification of the selection of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes were cast as follows: Votes For Votes Against Abstained Ratification of selection of KPMG LLP 14,058,234 8,055 3,042”

Verrica Pharmaceuticals Inc. shareholders approved Approval, on an advisory basis, of the compensation paid to the Company’s named executive officers, as disclosed in the Proxy Statement. at the 2026-06-05 meeting.

“Proposal No. 2 : Approval, on an advisory basis, of the compensation paid to the Company’s named executive officers, as disclosed in the Proxy Statement. The votes were cast as follows: Votes For Votes Against Abstained Advisory approval of named executive officer compensation 11,564,256 34,355 14,591 Broker Non-Votes: 2,456,129.”

Verrica Pharmaceuticals Inc. shareholders approved Election of two nominees to serve as directors until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified. at the 2026-06-05 meeting.

“Proposal No. 1 : Election of two nominees to serve as directors until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: Name Votes For Votes Withheld Paul B. Manning 11,543,142 70,060 Lawrence Eichenfield 11,523,540 89,662 Broker Non-Votes: 2,456,129. All nominees were elected.”

Verrica Pharmaceuticals Inc. reported Fourth Quarter and Full Year 2025 results: revenue $35.6 million.

“Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results – YCANTH ® net revenue grew 130% to $15.3 million in 2025, and selling, general and administrative expenses decreased by over 40%, when compared to 2024 – – Company earned $35.6 million in total revenue in 2025, up from $7.6 million in the prior year”

Verrica Pharmaceuticals Inc. entered into Securities Purchase Agreement with certain institutional investors valued at approximately $4.24115 million (effective 2025-11-23).

“On November 23, 2025, Verrica Pharmaceuticals, Inc. (the “ Company ”) entered into a Securities Purchase Agreement with certain institutional investors”

Verrica Pharmaceuticals Inc. issued Series C warrants to purchase 2,951,241 shares of Common Stock of warrant to institutional investors and other accredited investors for $4.24125 per share and accompanying Series C Warrant.

“Series C warrants to purchase 2,951,241 shares of Common Stock (the “ Series C Warrants ”). The purchase price per share of Common Stock and accompanying Series C Warrant is $4.24125 per share (the “ Purchase Price ”) and the purchase price for the Pre-Funded Warrants and accompanying Series C Warrant is the Purchase Price minus $0.0001 per Pre-Funded Warrant.”

Verrica Pharmaceuticals Inc. issued pre-funded warrants to purchase 5,305,164 shares of Common Stock of warrant to certain institutional investors and other accredited investors for Purchase Price minus $0.0001 per Pre-Funded Warrant.

“to the Purchasers in a private placement transaction (the “ Private Placement ”) an aggregate of (i) 6,499,826 shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 (“ Common Stock ”), (ii) with respect to certain Purchasers, pre-funded warrants to purchase 5,305,164 shares of Common Stock (the “ Pre-Funded Warrants ”) in lieu of Shares and”

Verrica Pharmaceuticals Inc. issued 6,499,826 shares of common stock to institutional investors and other accredited investors for $4.24125 per share.

“Series C warrants to purchase 2,951,241 shares of Common Stock (the “ Series C Warrants ”). The purchase price per share of Common Stock and accompanying Series C Warrant is $4.24125 per share (the “ Purchase Price ”) and the purchase price for the Pre-Funded Warrants and accompanying Series C Warrant is the Purchase Price minus $0.0001 per Pre-Funded Warrant.”

Christopher G. Hayes departed as Chief Legal Officer, Chief Compliance Officer and Corporate Secretary at Verrica Pharmaceuticals Inc..

“On April 22, 2025, Christopher G. Hayes notified Verrica Pharmaceuticals Inc. (the “ Company ”) that he will resign from his positions as the Company’s Chief Legal Officer, Chief Compliance Officer and Corporate Secretary effective as of April 30, 2025”

Gavin Corcoran was appointed as Director at Verrica Pharmaceuticals Inc..

“On March 31, 2025, the Board of Directors (the “ Board ”) of Verrica Pharmaceuticals Inc. (the “ Company ”) appointed Gavin Corcoran to serve as a director of the Company effective immediately.”

Verrica Pharmaceuticals Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“January 24, 2025, Verrica Pharmaceuticals, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Market, as the minimum bid price of the Company’s common stock was less than $1.00 per share for the previous 30 consecutive business days. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until July 23, 2025, to regain compliance”

Verrica Pharmaceuticals Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“January 24, 2025, Verrica Pharmaceuticals, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the listing of its common”

Jayson Rieger was appointed as President and Chief Executive Officer at Verrica Pharmaceuticals Inc..

“On November 1, 2024, the Board appointed Dr. Jayson Rieger as the Company’s President, Chief Executive Officer, and as member of the Board and designated him as the Company’s principal executive officer, each effective as of the Effective Date.”

Ted White resigned as President and Chief Executive Officer at Verrica Pharmaceuticals Inc..

“On November 1, 2024, Ted White notified the Company that he will resign from his positions as the Company’s President and Chief Executive Officer and as a member of the Company’s Board of Directors (the “ Board ”) effective as of November 5, 2024”

Craig Ballaron resigned as member of the Board of Directors at Verrica Pharmaceuticals Inc..

“On October 2, 2024, Craig Ballaron, a member of the Board of Directors (the “Board ”) of Verrica Pharmaceuticals Inc. (the “ Company ”), notified the Company that he was resigning from the Board and all committees of the Board, effective immediately.”

Verrica Pharmaceuticals Inc. announced a restructuring with charges of approximately $1.0 million, including a one-time charge totaling approximately $0.7 million in connection with one-time employee termination costs, including se (reduction of its workforce by 47 employees).

“On October 1, 2024, Verrica Pharmaceuticals Inc. (the “Company”) announced a reduction of its workforce by 47 employees, which the Company expects to be substantially completed by October 1, 2024. The Board of Directors of the Company approved these actions on September 23, 2024 in order to streamline operations, reduce costs, and preserve capital. As a result, the Company expects to incur total expenses of approximately $1.0 million, including a one-time charge totaling approximately $0.7 million in connection with one-time employee termination costs, including severance and other benefits, and an estimated deemed loss on vehicle sales of $0.3 million.”

Terence Kohler resigned as Chief Financial Officer at Verrica Pharmaceuticals Inc..

“On September 23, 2024, Terence Kohler, Chief Financial Officer of the Company, notified the Company of his resignation from his position, effective October 4, 2024 (the “Separation Date”), to pursue a new business opportunity.”

Joe Bonaccorso departed as Chief Commercial Officer at Verrica Pharmaceuticals Inc..

“on August 30, 2024, the Company and Joe Bonaccorso, the Company’s former Chief Commercial Officer, entered into a Release Agreement and a Consulting Agreement”

Joe Bonaccorso resigned as Chief Commercial Officer at Verrica Pharmaceuticals Inc..

“On August 21, 2024, Mr. Bonaccorso notified Verrica Pharmaceuticals Inc. (the “Company”) that he will resign from his position as Chief Commercial Officer of the Company, effective August 30, 2024.”

Verrica Pharmaceuticals Inc. amended Collaboration and License Agreement with Torii Pharmaceutical Co., Ltd. valued at Equally split costs of global Phase 3 clinical trial of YCANTH (VP-102) for common warts; Torii pays (effective 2024-05-14).

“On May 14, 2024 (the “Amendment Effective Date”), Verrica Pharmaceuticals Inc. (the “Company”) entered into an amendment (the Amendment”) to the Collaboration and License Agreement (the “Collaboration and License Agreement”) dated March 17, 2021, by and between the Company and Torii Pharmaceutical Co., Ltd. (“Torii” and together with the Company, the “Parties”).”

Verrica Pharmaceuticals Inc. reported first quarter ended March 31, 2024 results: revenue $3.2 million.

“Verrica recognized product revenue of $3.2 million in the first quarter of 2024.”

Verrica Pharmaceuticals Inc. reported financial results for the quarter and year ended December 31, 2023.

“On February 29, 2024, Verrica Pharmaceuticals Inc. (the “ Registrant ”) issued a press release announcing its financial results for the quarter and year ended December 31, 2023.”

Verrica Pharmaceuticals Inc. reported third quarter ended September 30, 2023 results: revenue $2.8 million.

“24, 2023 we received our first commercial sale of YCANTH TM to our exclusive distributor, FFF Enterprises Inc., resulting in net product revenue for the third quarter 2023 of $2.8 million upon its delivery to FFF. This first sale to FFF primarily represented stocking within the channel to allow patients to finally gain access to the first FDA-approved therapy for”

Verrica Pharmaceuticals Inc. reported financial results for six months ended June 30, 2023.

“Verrica Pharmaceuticals Inc. (the " Registrant ") issued a press release announcing its financial results for the quarter and six months ended June 30, 2023.”

Verrica Pharmaceuticals Inc. reported second quarter ended June 30, 2023 results: net income net loss on a GAAP basis was $11.0 million, or $0.24 per share, EPS net loss on a GAAP basis was $11.0 million, or $0.24 per share.

“Verrica Pharmaceuticals Inc. (the " Registrant ") issued a press release announcing its financial results for the quarter and six months ended June 30, 2023.”

Verrica Pharmaceuticals Inc. incurred credit facility of up to $125 million with OrbiMed Royalty & Credit Opportunities IV, LP at the higher of (x) the SOFR rate and (y) 4.00% plus 8.00% maturing July 26, 2028.

“The Credit Agreement provides for a five-year senior secured credit facility in an aggregate principal amount of up to $125 million”

Verrica Pharmaceuticals Inc. entered into Credit Agreement with OrbiMed Royalty & Credit Opportunities IV, LP valued at up to $125 million (effective 2023-07-26).

“On July 26, 2023 (the “ Closing Date ”), Verrica Pharmaceuticals Inc., a Delaware corporation (the “ Company ”) entered into a Credit Agreement (the “ Credit Agreement ”), by and between the Company, as borrower, and OrbiMed Royalty & Credit Opportunities IV, LP, a Delaware limited partnership (the “ Initial Lender ”), as a lender, and each other lender that may from time to time become a party thereto (each, including the Initial Lender, and together with their affiliates, successors, transferees and assignees, the “ Lenders ”), and OrbiMed Royalty & Credit Opportunities IV, LP, as administrative agent for the Lenders (in such capacity, the “ Administrative Agent ”).”

Verrica Pharmaceuticals Inc. shareholders approved Ratification of the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-06-08 meeting.

“Proposal No. 2 : Ratification of the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023. The votes were cast as follows: Votes For Votes Against Abstained Ratification of appointment of KPMG LLP 34,915,802 1,088 13,730”

Verrica Pharmaceuticals Inc. shareholders approved Election of three nominees to serve as directors until the 2026 annual meeting of stockholders and until their respective successors are elected and qualified. at the 2023-06-08 meeting.

“Proposal No. 1 : Election of three nominees to serve as directors until the 2026 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: Name Votes For Votes Withheld Craig Ballaron 16,697,734 370,566 Paul B. Manning 16,965,570 102,730 Lawrence Eichenfield 16,400,406 667,894 Broker Non-Votes: 17,862,320. All nominees were elected.”

Verrica Pharmaceuticals Inc. reported the first quarter ended March 31, 2023 results: revenue $37,000, net income $6.6 million, EPS $0.15 per share.

“million underwritten offering of common stock and pre-funded warrants. Financial Results First Quarter 2023 Financial Results • Verrica recognized collaboration revenues of $37,000 in the first quarter of 2023 compared to $0.4 million for the same period in 2022 related to the Collaboration and License Agreement with Torii Pharmaceutical Col, Ltd (“Torii”).”

Verrica Pharmaceuticals Inc. reported financial results for the fourth quarter and year ended December 31, 2022.

“On March 6, 2023, Verrica Pharmaceuticals Inc. (the “ Registrant ”) issued a press release announcing its financial results for the quarter and year ended December 31, 2022.”

Verrica Pharmaceuticals Inc. reported preliminary financial results for the year ended December 31, 2022.

“On February 21, 2023, Verrica Pharmaceuticals Inc. (the “ Company ”) reported that, as of December 31, 2022, it had approximately $34.3 million of cash and cash equivalents.”

Verrica Pharmaceuticals Inc. entered into Underwriting Agreement with Jefferies LLC valued at approximately $32.5 million (effective 2023-02-21).

“On February 21, 2023, Verrica Pharmaceuticals Inc. (the “C ompan y’) entered into an underwriting agreement (“ Underwriting Agreement ”) with Jefferies LLC (the “ Underwriter ”), to issue and sell 750,000 shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) at a price of $6.75 per share and, in lieu of Common Stock, certain investors were issued pre-funded warrants to purchase an aggregate of 4,064,814 shares of Common Stock at a price of $6.7499 (the “ Pre-Funded Warrants ”), which represents the per share price for the Shares less the $0.0001 per share exercise price for each Pre-Funded Warrant (the “ Offering ”).”

Verrica Pharmaceuticals Inc. reported nine months ended September 30, 2022 results: revenue $9.0 million, net income net loss of $18.6 million, EPS $0.58 per share.

“million, or $0.40 per share, for the same period in 2021. Year-to-Date September 2022 Financial Results • Verrica recognized license revenues related to the Torii Agreement of $9.0 million for the nine months ended September 30, 2022 compared to $12.0 million for the same period in 2021. The current period license revenue was related to an $8.0 million milestone”

Verrica Pharmaceuticals Inc. reported the third quarter ended September 30, 2022 results: revenue $8.3 million, net income $83 thousand, EPS $0.00 per share.

“Part 1 (safety and dose escalation) is expected to conclude in Q1 2023. Financial Results Third Quarter 2022 Financial Results • Verrica recognized license revenues of $8.3 million for the three months ended September 30, 2022 and no license revenue for the same period in 2021 related to the Collaboration and License Agreement (the “Torii Agreement”) with”

Terry Kohler was appointed as Chief Financial Officer at Verrica Pharmaceuticals Inc..

“On July 8, 2021 the board of directors (the “Board”) of the Company appointed Terry Kohler as the Company’s Chief Financial Officer, effective as of July 16, 2021.”

Brian Davis was terminated as Chief Financial Officer at Verrica Pharmaceuticals Inc..

“On July 6, 2021, Verrica Pharmaceuticals Inc. (the “Company”) notified Brian Davis that his employment as Chief Financial Officer of the Company would terminate, effective as of July 16, 2021.”